LY-2457546

N/A

Report date: 2022/01/14 13:23:58

NME

Base Information

Drug NameLY-2457546

Drug Alias NameLY-2457546

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionTEK receptor tyrosine kinase antagonistsVascular endothelial growth factor receptor 2 antagonistsTyrosine-protein kinase receptor FLT3 inhibitors +[4]

TargetsPlatelet-derived growth factor receptor betaVascular endothelial growth factor receptor 2Tyrosine-protein kinase receptor FLT3 +[4]

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesEli Lilly And Company

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesEli Lilly And Company

Active IndicationsN/A

Inactive IndicationsLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A